ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
558 articles with ImmunoGen Inc.
-
ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting
3/10/2022
ImmunoGen, Inc. today announced that multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in Phoenix, Arizona.
-
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022
3/1/2022
ImmunoGen, Inc. announced that on February 28, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 198,300 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.
-
ImmunoGen Reports Recent Progress and 2021 Financial Results
2/25/2022
ImmunoGen Inc. today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.
-
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
2/15/2022
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform.
-
Shares of ImmunoGen are climbing this morning after the company announced an antibody drug conjugate (ADCs) collaboration with Eli Lilly valued at up to $1.7 billion.
-
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
2/10/2022
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results.
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference
2/4/2022
ImmunoGen, Inc. today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference.
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022
2/1/2022
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on January 31, 2022, the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 525,600 shares of its common stock to four new employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2022
1/3/2022
ImmunoGen Inc. announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 16,800 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
12/29/2021
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference.
-
ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
12/12/2021
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia were presented in an oral session at the 63rd American Society of Hematology Annual Meeting.
-
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Dec 06, 2021
12/6/2021
ImmunoGen, Inc. announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common stock, which reflects the exercise in full by the underwriters of their option to purchase up to 5,850,000 additional shares of common stock, and pre-funded warrants to purchase 27,363,636 shares of its common stock.
-
Exceeding Expectations, ImmunoGen Eyes 2022 Approval for Ovarian Cancer Drug Mirvetuximab Soravta...
12/1/2021
ImmunoGen shares positive results from its Phase III SORAYA trial, which is evaluating the use of mirvetuximab soravtansine for treating ovarian cancer. -
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
11/30/2021
ImmunoGen Inc. today announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin® (bevacizumab).
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 24, 2021
11/24/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 327,700 shares of its common stock to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
11/17/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Tracey L. McCain, Esq. to its Board of Directors.
-
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
11/16/2021
ImmunoGen Inc. today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.